Patents - Global Data - Dimensions
Application
HIGHLY POTENT ISVD COMPOUNDS CAPABLE OF SUBSTITUTING FOR FVIII(A)
Applicants
- Novo Nordisk (Denmark)
[NORA names: Novo Nordisk; Private Research; Denmark; Europe, EU; Nordic; OECD]
Abstract
The present invention provides ISVD polypeptide derivatives capable of binding coagulation Factor IX(a) and Factor X(a) which are highly potent and provide a sufficiently long half-life such to allow for effective subcutaneous—as well as peroral administration. The ISVD polypeptides derivatives disclosed herein are thus suitable for treatment of haemophilia A, haemophilia A with inhibitors and acquired haemophilia A by various routes of administration including subcutaneous and peroral administration.
Patent Family Records (6)
HIGHLY POTENT ISVD COMPOUNDS CAPABLE OF SUBSTITUTING FOR FVIII(A)
Novo Nordisk (Denmark), Novo Nordisk AS VEGGE ANDREAS, STEFFENSEN SOREN, BUYSE MARIE ANGE, (...more)
2024, US-20240067944-A1
HIGHLY POTENT ISVD COMPOUNDS CAPABLE OF SUBSTITUTING FOR FVIII(A)
NOVO NORDISK AS, Novo Nordisk (Denmark) VEGGE ANDREAS, FULLE SIMONE, NORRMAN MATHIAS, (...more)
2024, TW-202409091-A
Highly potent ISVD compounds capable of substituting for FVIII(a)
NOVO NORDISK A, Novo Nordisk (Denmark) VEGGE ANDREAS, FULLE SIMONE, NORRMAN MATHIAS, (...more)
2024, KR-20240007881-A
Highly potent ISVD compounds that can replace FVIII(a)
Novo Nordisk (Denmark), Novo Nordisk AS アンドレアス・ヴェッゲ, エヴァ・ヨハンソン, エヴリン・デ・タヴェルニエ, (...more)
2024, JP-7459354-B2
Highly potent ISVD compounds that can replace FVIII(a)
Novo Nordisk (Denmark), Novo Nordisk AS アンドレアス・ヴェッゲ, エヴァ・ヨハンソン, エヴリン・デ・タヴェルニエ, (...more)
2024, JP-2024073606-A
Highly Potent ISVD Compounds that Can Replace FVIII(a)
Novo Nordisk (Denmark), Novo Nordisk AS ANDREAS VEGGE, SIMONE FULLE, MATHIAS NORRMAN, (...more)
2024, JP-2024020151-A